ArticlePloS one2025
Super-enhancer-associated LINC00963 promotes metastasis of gastric cancer through epithelial-mesenchymal transition.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LINC00963 targeting miR-98-5p exacerbates sepsis-induced myocardial injury.Internal and emergency medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn clinical practice, gastric cancer (GC) is a common malignancy with high morbidity. Accumulating research has revealed that lncRNAs are involved in the development and metastasis of tumor tissues in multiple cancers. As reported, LINC00963, a typical lncRNA is aberrantly expressed in gastric cancer. However, the underlying mechanisms of super-enhancers mediating remain unclear. MATERIALS AND
methodsThe GC cell line enhancer-super-enhancer data were downloaded and analyzed from the NCBI database (GSE75595). Combined RT-qPCR and Sanger sequencing were employed to identify three variants of LINC00963 in gastric cell lines and peripheral blood samples from gastric cancer patients. Western blot was used to detect the expression level of epi-thelial-mesenchymal transition (EMT)-related proteins. Transwell assays were applied to assess the cell invasion and migration. A xenograft model was applied to simulate the tumor development process, during which the effect of LINC00963 on promoting tu-morigenesis were investigated.
resultsAnalysis of the GC cell line enhanc-er-super-enhancer data revealed a high expression of LINC00963 driven by su-per-enhancer. The variant 1 and variant 2 of LINC00963 exhibited high expression in GC cell line and the peripheral blood of gastric cancers. LINC00963 expression in the GC cell line was reduced after exposure to a low dose of the bromodomain and extraterminal inhibitor JQ1. Down-regulation of LINC00963 variant 1 resulted in decreased levels of β-catenin and ZEB1 proteins, and the protein expression levels of several marker proteins related to EMT, such as Vimentin, N-cadherin were observed to decrease (Fig 1).
conclusionThis study demonstrated that the super-enhancer-associated LINC00963 promoting tumor metastasis in gastric cancer through EMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.